Related Experiment Video
Updated: Oct 9, 2025
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Recombinant Human Growth Hormone Inhibits Lipotoxicity, Oxidative Stress, and Apoptosis in a Mouse Model of Diabetic
Zuowei Pei1,2, Xiang Wang1,3, Chenguang Yang1
1Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Insights
Recombinant human growth hormone (rhGH) protects against diabetic cardiomyopathy in mice by improving heart function and reducing oxidative stress and apoptosis. This suggests rhGH as a potential therapy for type 2 diabetes-related heart conditions.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
Background:
- Recombinant human growth hormone (rhGH) shows protective effects against cardiac damage.
- Diabetic cardiomyopathy is a significant complication of type 2 diabetes, characterized by cardiac dysfunction.
- Understanding the mechanisms of rhGH in diabetic hearts is crucial for therapeutic development.
Purpose of the Study:
- To investigate the effects of rhGH on cardiac function in a mouse model of type 2 diabetes (db/db mice).
- To elucidate the underlying mechanisms, including oxidative stress, lipid metabolism, and apoptosis, by which rhGH impacts diabetic cardiomyopathy.
Main Methods:
- C57BL/6J and db/db mice were treated with rhGH for 16 weeks.
- Evaluated metabolic parameters, cardiac function and morphology, cardiac oxidative stress, lipid metabolism, and apoptosis.
- Compared outcomes between rhGH-treated and control groups.
Main Results:
- rhGH did not significantly alter fasting blood glucose levels in db/db mice.
- rhGH treatment improved cardiac function and reduced cardiac oxidative stress and apoptosis in db/db mice.
- rhGH ameliorated cardiac dysfunction by inhibiting lipotoxicity in diabetic mice.
Conclusions:
- rhGH demonstrates protective effects against diabetic cardiomyopathy in mice, independent of glycemic control.
- rhGH exerts its cardioprotective effects by reducing oxidative stress, apoptosis, and lipotoxicity in the diabetic heart.
- rhGH is a promising therapeutic candidate for treating diabetic cardiomyopathy associated with type 2 diabetes.
Abstract:
Recombinant human growth hormone (rhGH), widely used in clinical studies, exerts protective effects against cardiac damage. Here, we investigated the effects and mechanisms underlying the effects of rhGH on cardiac functions in db/db mice. C57BL/6J and db/db mice were subjected to rhGH treatment. Metabolic parameters, cardiac function and morphology, oxidative stress, lipid metabolism, and apoptosis were evaluated 16 weeks after rhGH treatment. Although rhGH did not significantly affect fasting blood glucose levels in db/db mice, it protected against diabetic cardiomyopathy, by improving cardiac function and reducing oxidative stress in the heart. In addition, rhGH treatment exhibited anti-apoptotic effects in the heart of db/db mice. The rhGH treatment, besides inhibiting oxidative stress and apoptosis, ameliorated cardiac dysfunction by inhibiting lipotoxicity in mice with type 2 diabetes. These findings suggest that rhGH is a promising therapeutic agent for diabetic cardiomyopathy.
